The distinctive nature of HER2-positive breast cancers.

@article{Burstein2005TheDN,
  title={The distinctive nature of HER2-positive breast cancers.},
  author={H. Burstein},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 16},
  pages={
          1652-4
        }
}
  • H. Burstein
  • Published 2005
  • Medicine
  • The New England journal of medicine
  • The history of HER2 and trastuzumab treatment is a triumphal narrative of translational research. Dr. Harold Burstein writes that like all good stories, this one has a profound lesson: not all breast cancers are the same. 

    Topics from this paper.

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2 single domain antibody (sdAb) (Product Code Name: 99mTc-NM02 and 188Re-NM02) SPECT/CT imaging of HER2… Expand
    ConditionsBreast Cancer
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal… Expand
    ConditionsBreast Cancer
    InterventionBiological, Drug
    INTERVENTIONAL CLINICAL TRIAL
    Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front… Expand
    ConditionsMetastatic Breast Cancer
    InterventionDrug
    Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis.
    • 707
    • PDF

    References

    Publications referenced by this paper.